X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.biospace.com/article/releases/new-pediatric-and-secondary-endpoint-data-from-rivipansel-phase-3-reset-trial-presented-at-the-annual-scientific-conference-on-sickle-cell-and-thalassemia-ascat-meeting/
https://www.fiercebiotech.com/biotech/glycomimetics-nearly-cut-half-as-pfizer-partnered-phase-3-drug-flops
https://www.prnewswire.com/news-releases/medicines360-and-allergan-present-six-year-clinical-data-from-largest-ongoing-phase-3-study-of-an-intrauterine-system-in-the-us-300843478.html
https://www.forbes.com/sites/greatspeculations/2018/07/02/how-sensitive-is-pfizer-to-rd-expense-changes/#1a6f7f16230f
Market Place
Share 
